October 13, 2018

ME: 23andMe Holding Co. Stock

by Wilton Risenhoover

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M)	57.62
Enterprise Value ($M)	-68.98
Book Value ($M)	101.93
Book Value / Share	5.82
Price / Book	0.57
NCAV ($M)	-28.22
NCAV / Share	-1.61
Price / NCAV	-2.04

Profitability (mra)
Return on Invested Capital (ROIC)	-3.54
Return on Assets (ROA)	-0.77
Return on Equity (ROE)	-0.98

Liquidity (mrq)
Quick Ratio	1.14
Current Ratio	1.24

Balance Sheet (mrq) ($M)
Current Assets	188.78
Assets	318.94
Liabilities	217.01
Debt	n/a
Equity	n/a

Income Statement (mra) ($M)
Revenue	219.64
Operating Income	-321.36
Net Income	-666.70

Cash Flow Statement (mra) ($M)
Cash From Operations	-164.32
Cash from Investing	-9.63
Cash from Financing	3.58
(click for more detail)

File Date	Form	Activist 13D/G Investors	Ownership (%)	Change (%)
11-15	13D/A	ABeeC 2.0, LLC	22.80	0.14
11-15	13D/A	Glaxosmithkline Plc	9.50	-95.00
11-13	13G	Zentree Investments Ltd	5.02
11-12	13G/A	Vanguard Group Inc	4.58	0.00
10-21	13G/A	Sc Us (ttgp), Ltd.	3.90	-95.00
07-08	13G/A	BlackRock, Inc.	1.40	-79.27

Top 13F Investors	Shares (1000)	Change (%)	Value ($1000)	Change (%)
(click for more detail)

Date	Insider Trades	Code	Shares	Value
(click for more detail)

File Date	Form	SEC Filings
2024-11-12	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPO
2024-08-08	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PU
2024-05-30	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT
2024-02-07	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 o TRANSITION REPOR
(click for more detail)

Short Volume
Market Date	Short Volume	Total Volume	Short Volume Ratio
2024-11-26	141,834	296,036	47.91
2024-11-25	128,236	533,248	24.05
2024-11-22	121,250	511,155	23.72
2024-11-21	68,164	292,486	23.31
(click for more detail)

Similar Companies
LTRN – Lantern Pharma Inc.	MBIO – Mustang Bio, Inc.
MBRX – Moleculin Biotech, Inc.	MEIP – MEI Pharma, Inc.
MIRA – MIRA Pharmaceuticals, Inc.

Financial data and stock pages provided by
Fintel.io

Related